ICURE PHARMACEUTICAL INCORPORATION |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,375 KRW | +28.38% |
|
+30.71% | +13.64% |
| Sales 2022 | 59.37B 42.86M | Sales 2023 | 56.81B 41.01M | Capitalization | 78.1B 56.39M |
|---|---|---|---|---|---|
| Net income 2022 | -41.77B -30.16M | Net income 2023 | -31.42B -22.69M | EV / Sales 2022 | 1.9 x |
| Net Debt 2022 | 33.22B 23.99M | Net Debt 2023 | 67.85B 48.99M | EV / Sales 2023 | 2.57 x |
| P/E ratio 2022 |
-1.42
x | P/E ratio 2023 |
-2.5
x | Employees | 199 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 84.43% |
More Fundamentals
* Assessed data
More news
| 1 day | +28.38% | ||
| 1 week | +30.71% | ||
| 1 month | +25.40% | ||
| 3 months | +6.98% | ||
| 6 months | +14.18% | ||
| Current year | +13.64% |
1 week
1 817.00
2 405.00
1 month
1 800.002 405.00
Current year
1 800.003 470.00
1 year
1 775.003 595.00
3 years
1 775.0020 625.00
5 years
1 775.0028 645.83
10 years
1 775.0028 645.83
| Managers | Title | Age | Since |
|---|---|---|---|
Choi Young
CEO | Chief Executive Officer | 64 | - |
Hyeon-Sik Jeong
CTO | Chief Tech/Sci/R&D Officer | 62 | - |
Sang-Yoon Jeong
BRD | Director/Board Member | 58 | 07-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Choi Young
CEO | Chief Executive Officer | 64 | - |
Sang-Yoon Jeong
BRD | Director/Board Member | 58 | 07-12-31 |
Hyeon-Sik Jeong
CTO | Chief Tech/Sci/R&D Officer | 62 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 2,375 | +28.38% | 14,396,200 |
| 24-05-30 | 1,850 | -5.61% | 359,310 |
| 24-05-29 | 1,960 | +1.45% | 401,487 |
| 24-05-28 | 1,932 | -5.76% | 643,579 |
| 24-05-27 | 2,050 | +12.82% | 5,513,443 |
End-of-day quote Korea S.E., May 30, 2024
More quotes
Icure Pharmaceutical Incorporation is a Korea-based company mainly engaged in the production and sale of cosmetics. Along with subsidiaries, the Company operates its business through two segments. The Cosmetic segment is involved in the manufacturing and sale of cosmetics including basic cosmetics, mask packs, and patches. In addition, it is also engaged in the production and sale of body, hair care products and fragrances. The cosmetics are sold under the names of Botalinum, Mediheal N.M.F, Meditime, among others. The Pharmaceutical segment is engaged in the manufacturing and sale of over the counter (OTC) drugs, ethical the counter (ETC) drugs, as well as quasi drugs. The OTC drugs include anti-inflammatory analgesics and dementia treatments. The Company distributes its products within the domestic market and to overseas markets.
Sector
Personal Products
Calendar
2024-08-12
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +13.64% | 64.18M | |
| +0.32% | 262B | |
| +18.76% | 20.37B | |
| -.--% | 19.29B | |
| +16.91% | 12.64B | |
| -16.59% | 8.94B | |
| +33.93% | 8.62B | |
| +9.55% | 5.93B | |
| -12.08% | 3.92B | |
| -16.83% | 3.84B |
- Stock Market
- Equities
- A175250 Stock
